Mylan (NASDAQ:MYL) received a $50.00 price objective from equities research analysts at Deutsche Bank in a research note issued on Wednesday. The firm presently has a “buy” rating on the stock. Deutsche Bank’s price target points to a potential upside of 8.72% from the stock’s current price.

A number of other research analysts have also recently issued reports on the company. TheStreet upgraded Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Wells Fargo & Co set a $43.00 price objective on Mylan and gave the company a “hold” rating in a research note on Thursday, January 18th. Zacks Investment Research upgraded Mylan from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Goldman Sachs Group lifted their price objective on Mylan from $46.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, January 11th. Finally, Citigroup reiterated a “buy” rating and set a $58.00 price objective (up previously from $48.00) on shares of Mylan in a research note on Thursday, January 4th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $44.65.

Mylan (NASDAQ:MYL) opened at $45.99 on Wednesday. The company has a market capitalization of $24,740.43, a P/E ratio of 9.81, a PEG ratio of 1.25 and a beta of 1.38. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. Mylan has a one year low of $29.39 and a one year high of $47.82.

Mylan (NASDAQ:MYL) last released its earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing the Zacks’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.38 EPS. analysts expect that Mylan will post 4.55 earnings per share for the current year.

In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of Mylan stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total value of $3,375,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.69% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the business. Pzena Investment Management LLC grew its holdings in shares of Mylan by 84.1% in the third quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after acquiring an additional 10,381,697 shares during the period. Schroder Investment Management Group grew its holdings in shares of Mylan by 74.7% in the third quarter. Schroder Investment Management Group now owns 3,026,172 shares of the company’s stock worth $93,388,000 after acquiring an additional 1,294,400 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Mylan by 70.8% in the third quarter. Russell Investments Group Ltd. now owns 2,584,880 shares of the company’s stock worth $81,079,000 after acquiring an additional 1,071,089 shares during the period. Jennison Associates LLC bought a new stake in shares of Mylan in the fourth quarter worth $40,769,000. Finally, GMT Capital Corp bought a new stake in shares of Mylan in the third quarter worth $30,172,000. 75.07% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Deutsche Bank Analysts Give Mylan (MYL) a $50.00 Price Target” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://theolympiareport.com/2018/01/26/deutsche-bank-analysts-give-mylan-myl-a-50-00-price-target.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.